https://pittplusme.org/study/1785
Moderate to Severe Hidradenitis Suppurativa Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have moderate to severe hidradenitis suppurativa (HS)? If so, you may be able to participate in a study to see if a drug called upadacitinib (used to treat rheumatoid arthritis) is safe and effective to treat moderate to severe HS. This study involves 11 visits over up to 57 weeks. Compensation is provided.
IRB: SSU00123690
- AbbVie - US - M20-040, A Phase 2, Multicenter, Randomized, Placebo- Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa (Pro00042662)
AGE:
18 and up
DURATION:
Up to 57 weeks
VISITS:
11
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$51 per visit
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.